Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06861244 · ClinicalTrials.gov registry record · Phase 2

Embryonal Tumor With Multilayered Rosettes

A Phase 2 study of Embryonal Tumor With Multilayered Rosettes and Embryonal Tumor With Multilayered Rosettes, Nos, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
4
Study locations

NCT06861244: Recruiting Phase 2 study of Embryonal Tumor With Multilayered Rosettes and Embryonal Tumor With Multilayered Rosettes, Nos, sponsored by University of California, San Francisco.

NCT06861244 is a Phase 2 study of Embryonal Tumor With Multilayered Rosettes and Embryonal Tumor With Multilayered Rosettes, Nos that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 70 participants, below the 134-participant average among 3 other Embryonal Tumor With Multilayered Rosettes trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06861244, a Phase 2 study of Embryonal Tumor With Multilayered Rosettes and Embryonal Tumor With Multilayered Rosettes, Nos, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
4
Study locations

Study Summary

This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).

Primary Outcome

The median PFS6 is defined as the median number of months for participants in Cohort 1 who have remained progression-free from the date of initial surgical resection until 6 months.

Interventions

  • DRUG Temozolomide
  • RADIATION Radiotherapy (RT)
  • DRUG Chemotherapy Drug, Cancer - Physician's Choice
  • PROCEDURE Non-Investigational Surgical Resection
  • PROCEDURE Tumor Tissue Sample

Study Locations (4)

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California, San Francisco - San Francisco

Maryland

  • Johns Hopkins University - Baltimore

Missouri

  • Washington University in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-03-06
Est. Completion 2032-03-31
Phase Phase 2

What NCT06861244 shows while recruiting

NCT06861244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 134-participant average among 3 other Embryonal Tumor With Multilayered Rosettes trials with a reported enrollment target (48% lower).

The record links to 2 conditions, with Embryonal Tumor With Multilayered Rosettes appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.

NCT06861244 reports a single indexed study location in Alabama, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT06861244 about?

NCT06861244 is a clinical study titled "Embryonal Tumor With Multilayered Rosettes". This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).

What is the current status of trial NCT06861244?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-03-06. Estimated completion is 2032-03-31.

What conditions does trial NCT06861244 study?

This clinical trial studies the following conditions: Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos.

What interventions are being tested in trial NCT06861244?

The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RT) (RADIATION), Chemotherapy Drug, Cancer - Physician's Choice (DRUG), Non-Investigational Surgical Resection (PROCEDURE), Tumor Tissue Sample (PROCEDURE).

Who is sponsoring clinical trial NCT06861244?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06861244 being conducted?

This trial has 4 study locations across Alabama, California, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Embryonal Tumor With Multilayered Rosettes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06861244, the US trial registry maintained by the National Library of Medicine. NCT06861244 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.